228 related articles for article (PubMed ID: 31636088)
1. Pulmonary hypertension and chronic lung disease: where are we headed?
Elia D; Caminati A; Zompatori M; Cassandro R; Lonati C; Luisi F; Pelosi G; Provencher S; Harari S
Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31636088
[TBL] [Abstract][Full Text] [Related]
2. Somatic Mutations: The Next Frontier in Demystifying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis?
Yan X; Kaminski N
Am J Respir Crit Care Med; 2023 Dec; 208(11):1150-1151. PubMed ID: 37856835
[No Abstract] [Full Text] [Related]
3. Toward Early Diagnosis of Pulmonary Hypertension: Lessons From Oz.
Maron BA; Wertheim BM
J Am Coll Cardiol; 2019 Jun; 73(21):2673-2675. PubMed ID: 31146811
[No Abstract] [Full Text] [Related]
4. Updated Perspectives on Pulmonary Hypertension in COPD.
Blanco I; Tura-Ceide O; Peinado VI; Barberà JA
Int J Chron Obstruct Pulmon Dis; 2020; 15():1315-1324. PubMed ID: 32606641
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary hypertension in chronic obstructive pulmonary disease.
Gredic M; Blanco I; Kovacs G; Helyes Z; Ferdinandy P; Olschewski H; Barberà JA; Weissmann N
Br J Pharmacol; 2021 Jan; 178(1):132-151. PubMed ID: 31976545
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary Hypertension: A Brief Guide for Clinicians.
Mandras SA; Mehta HS; Vaidya A
Mayo Clin Proc; 2020 Sep; 95(9):1978-1988. PubMed ID: 32861339
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary arterial hypertension and COVID-19.
Avellanas Chavala ML
Med Intensiva (Engl Ed); 2020 Dec; 44(9):577-579. PubMed ID: 32571526
[No Abstract] [Full Text] [Related]
8. The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment.
King CS; Shlobin OA
Chest; 2020 Oct; 158(4):1651-1664. PubMed ID: 32387520
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life.
DuBrock HM; Nathan SD; Reeve BB; Kolaitis NA; Mathai SC; Classi PM; Nelsen AC; Olayinka-Amao B; Norcross LN; Martin SA
Pulm Circ; 2021; 11(2):20458940211005641. PubMed ID: 33868642
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of Chronic Obstructive Pulmonary Disease Patients with Pulmonary Hypertension Assessed by Echocardiography in a Three-Year Observational Cohort Study.
Nakayama S; Chubachi S; Sakurai K; Irie H; Tsutsumi A; Hashiguchi M; Itabashi Y; Murata M; Nakamura H; Asano K; Fukunaga K
Int J Chron Obstruct Pulmon Dis; 2020; 15():487-499. PubMed ID: 32184586
[TBL] [Abstract][Full Text] [Related]
11. Treating Hypertension in Chronic Obstructive Pulmonary Disease.
Finks SW; Rumbak MJ; Self TH
N Engl J Med; 2020 Jan; 382(4):353-363. PubMed ID: 31971680
[No Abstract] [Full Text] [Related]
12. Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights.
Ruffenach G; Hong J; Vaillancourt M; Medzikovic L; Eghbali M
Respir Res; 2020 Nov; 21(1):303. PubMed ID: 33208169
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.
Rajagopal K; Bryant AJ; Sahay S; Wareing N; Zhou Y; Pandit LM; Karmouty-Quintana H
Br J Pharmacol; 2021 Jan; 178(1):172-186. PubMed ID: 32128790
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the management of pulmonary hypertension with interstitial lung disease.
Waxman AB; Elia D; Adir Y; Humbert M; Harari S
Eur Respir Rev; 2022 Sep; 31(165):. PubMed ID: 35831007
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary hypertension in interstitial lung disease and in chronic obstructive pulmonary disease: different entities?
Piccari L; Aguilar-Colindres R; Rodríguez-Chiaradía DA
Curr Opin Pulm Med; 2023 Sep; 29(5):370-379. PubMed ID: 37395513
[TBL] [Abstract][Full Text] [Related]
16. Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials.
Shioleno AM; Ruopp NF
Clin Chest Med; 2021 Mar; 42(1):59-70. PubMed ID: 33541617
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials in group 3 pulmonary hypertension.
Harder EM; Waxman AB
Curr Opin Pulm Med; 2020 Sep; 26(5):391-396. PubMed ID: 32657833
[TBL] [Abstract][Full Text] [Related]
18. Natural compounds targeting mitochondrial dysfunction: emerging therapeutics for target organ damage in hypertension.
Liao X; Han Y; He Y; Liu J; Wang Y
Front Pharmacol; 2023; 14():1209890. PubMed ID: 37397478
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology and new advances in pulmonary hypertension.
Bousseau S; Sobrano Fais R; Gu S; Frump A; Lahm T
BMJ Med; 2023; 2(1):e000137. PubMed ID: 37051026
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
